Last reviewed · How we verify
Ramosetron, Aprepitant, Dexamethasone
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: 5-HT3 antagonism, NK1 antagonism, and corticosteroid action.
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: 5-HT3 antagonism, NK1 antagonism, and corticosteroid action. Used for Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | Ramosetron, Aprepitant, Dexamethasone |
|---|---|
| Also known as | Nasea, Emend, ramosetron(nasea), aprepitant(emend) |
| Sponsor | Hallym University Medical Center |
| Drug class | 5-HT3 antagonist / NK1 antagonist / corticosteroid combination |
| Target | 5-HT3 receptor, NK1 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Ramosetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the central nervous system. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple pathways. Together, these agents provide comprehensive coverage of the major pathways involved in CINV.
Approved indications
- Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
Key clinical trials
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (PHASE4)
- Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (PHASE2)
- Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone (PHASE3)
- Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: